Prokinetic Drugs Available for Esophageal Dysmotility
The available prokinetic drugs for esophageal dysmotility include metoclopramide, domperidone (outside the U.S.), and erythromycin, though evidence supporting their routine use is weak and their benefits must be carefully weighed against significant adverse effects. 1
Primary Prokinetic Options
Metoclopramide
- FDA-approved for gastroparesis but carries a black box warning for serious adverse effects 2
- Adverse effects occur in 11-34% of patients, including:
- Extrapyramidal signs (acute dystonic reactions, drug-induced parkinsonism, akathisia)
- Tardive dyskinesia
- Drowsiness and restlessness 3
- FDA recommends against use beyond 12 weeks due to these risks 2
- Should be reserved for severe cases unresponsive to other therapies 2
Domperidone
- Available outside the United States 2
- In a randomized trial of 148 SSc patients with esophageal symptoms, domperidone showed improvement in GERD severity with 13.2% non-responders 1
- Generally better tolerated than metoclopramide with fewer central nervous system effects
Erythromycin
- Acts as a motilin receptor agonist with prokinetic effects 4, 5
- Only effective for short-term use due to tachyphylaxis (tolerance development) 2
- Macrolides increase lower esophageal sphincter pressure and potentiate gastric and small bowel motility 4
- In pediatric populations, erythromycin has numerous controlled trials demonstrating efficacy with uncommon adverse reactions 5
Critical Evidence Limitations
Guidelines unequivocally state there is insufficient evidence to support routine use of any prokinetic agent for esophageal dysmotility. 3 The 2013 Pediatrics guideline explicitly notes that "efforts to design a prokinetic agent with benefits that outweigh adverse effects has proven difficult" 3.
Emerging and Alternative Agents
Newer Prokinetic Options (Limited Evidence for Esophageal Use)
- Prucalopride (5-HT4 receptor agonist): Shown effectiveness in SSc-related constipation 1
- Buspirone (5-HT1A receptor agonist): Single-dose study showed increased lower esophageal sphincter pressure in SSc patients 1
Historical Agents (No Longer Recommended)
- Cisapride: No longer commercially available in the United States due to cardiac arrhythmia risk (long QT syndrome) 3, 6
- Bethanechol: Limited by side effects and uncertain efficacy 3
Clinical Decision Algorithm
When considering prokinetic therapy for esophageal dysmotility:
First-line approach: Address underlying causes and optimize acid suppression with PPIs if GERD is present 1
If prokinetic trial warranted (symptomatic motility disturbances despite acid suppression):
- Outside U.S.: Consider domperidone as first choice (better safety profile)
- Within U.S.: Erythromycin for short-term trial (2-4 weeks maximum before tachyphylaxis)
- Severe refractory cases only: Metoclopramide with close monitoring, limited to <12 weeks
Monitor closely for:
- Extrapyramidal symptoms (metoclopramide)
- Loss of efficacy (erythromycin tachyphylaxis)
- GI side effects (all agents)
Critical Caveats
- The 2025 EULAR guidelines for systemic sclerosis recommend considering prokinetic drugs for symptomatic motility disturbances, but acknowledge the substantial unmet need for better GI symptom control 1
- Prokinetic agents improve contractility of the esophageal body, increase lower esophageal sphincter pressure, and increase gastric emptying rate, but clinical efficacy remains inconsistent 3
- In pediatric GERD specifically, guidelines state prokinetics should not be routinely used given the risk-benefit profile 3, 7
- Research priority: The EULAR task force endorsed high priority for future studies on GI manifestations and treatment efficacy 1
The evidence consistently demonstrates that while these agents have theoretical benefits for esophageal dysmotility, their clinical utility is limited by adverse effects, tachyphylaxis, and lack of robust efficacy data specific to esophageal disorders.